Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PFIZER INC Director's Dealing 2024

Feb 27, 2024

29831_dirs_2024-02-27_8e930e62-2917-4b03-9e7d-4acdb0df16a3.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PFIZER INC (PFE)
CIK: 0000078003
Period of Report: 2024-02-23

Reporting Person: BOURLA ALBERT (Director, Chairman & CEO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-02-23 Common Stock M 127674.0000 $27.3400 Acquired 439748.0000 Direct
2024-02-23 Common Stock F 8831.0000 $27.7600 Disposed 430917.0000 Direct
2024-02-23 Common Stock F 103178.0000 $27.3700 Disposed 327739.0000 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-02-23 Stock Appreciation Rights $27.3400 M 127674.0000 Disposed 2024-02-23 Common Stock (127674.0000) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 4750.0000 Indirect

Footnotes

F1: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

F2: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

F3: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F4: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.